Ambulatory blood pressure monitoring (ABPM) is important for the management of patients with hypertension as it allows more sensitive and specific cardiovascular risk stratification compared to office blood pressure (BP) measurement. [1] [2] [3] International guidelines recommend ABPM in patients with resistant hypertension to exclude pseudo-resistance and to more accurately assess BP control by treatment. 4 ABPM with 24-hour, day and night average BP values correlate more closely to hypertensive or diabetic end-organ damage than office BP values. [5] [6] [7] Nighttime BP is more closely related to cardiovascular morbidity and mortality than daytime BP. 3, 8 High nighttime BP and non-dipping patterns have been associated with increased sympathetic activity in hypertensives. 9 Catheter-based renal denervation (RDN) offers a new approach to interrupt renal sympathetic innervation and has been shown to reduce renal and total body norepinephrine spillover. [10] [11] [12] RDN significantly reduced office systolic and diastolic BP in patients with resistant hypertension, 13, 14 reduced left ventricular mass and improved diastolic function 15 and glucose metabolism 16 without negatively affecting renal function 17 or causing chronotropic incompetence during exercise. 18 However, only limited information about the impact of RDN on daytime, nighttime and average BP from the Symplicity HTN-2 trial is available. 13 Furthermore, information about the effectiveness of RDN according to patients' baseline characteristics and predictors of response are lacking. This study aimed to investigate the effects of RDN on out-ofoffice BP by 24-hour ABPM and assessed the potential correlates of response to treatment in the largest cohort of patients with true resistant and pseudo-resistant hypertension analyzed so far.
Methods
Local ethic committees approved the study. All patients gave written informed consent and were
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All patients underwent a complete history and physical examination, assessment of vital signs, and review of medication. Patients were interviewed whether they had taken their complete medication at defined doses. Treating physicians and patients were instructed not to change medications except when medically required.
Office SBP, DBP and PP as well as ABPM readings were obtained at entry, and 3, 6, and 12 months following treatment. Office BP readings were taken in a seated position with an automatic oscillometric Omron HEM-705 monitor (Omron Healthcare, Vernon Hills, IL, USA) after 5 minutes of rest according to the Standard Joint National Committee VII Guidelines. 19 At baseline, BP was measured at each arm and the arm with the higher BP was used for all subsequent readings. Averages of the triplicate measures were calculated and used for analysis.
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Results
Patient characteristics of the entire patient population (true resistant and pseudo-resistant) are considered at target when daytime and nighttime values were <135/85 and <120 0/7 /7 /70 0 0 mm mm mHg Hg Hg, , espectively. The RDN procedure was performed as previously described.
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Discussion
Renal denervation offers a novel and well-tolerated approach to selectively interrupt sympathetic fibers and effectively reduce systolic and diastolic office BP. 11, 12 Recently, concerns have been raised that RDN might not reduce ABP equally effective. 22 The results of the present multicenter study in more than 300 patients now confirm that RDN significantly reduces office and 24-hour average, daytime and nighttime BP in patients with true-resistant hypertension and increases the rate of patients controlled to target BP values, both according to office BP and ABPM. Of note, office BP also declined in pseudo-resistant patients.
Blood pressure varies throughout the circadian period with a prolonged decrease during 8.6/8.6/9.7 mmHg at 3, 6, and 12 months, respectively (p<0.001 for all). No dif ffe fe ere enc n n es es e e e exi xi xist st s e ed concerning medication reductions (p=0.524) or increases (p=0.399) between true-resistant and ps seu eu udo do do-r -res es esis is ista t tant t p p pa at atients. Figure 4 illustrates the he e d di istribution of of of office e a a an n nd daytime BP levels at b ba ase e eli l ne pre-p pro roce ce c du dur re e a a and nd nd a a at t 3 3, 3, 6, 6, 6, a a and nd d 1 1 12 m mo mon nths s s p p post t-t-p pr pro oc ce ed edur ur re. .
nocturnal sleep. 1 Daytime BP is more variable than nighttime BP in terms of different physical and mental activity and nighttime BP is closely related to sympathetic outflow to the heart and the muscle vasculature. 23 Sympathetic activation has been shown to be a major contributor in the development and progression of hypertension and represents a potential mechanism for the daynight BP difference. 24 Recently, a close inverse relationship between the degree of sympathetic activation and the magnitude of the nighttime drop in SBP and DBP has been reported. 9 The daynight BP differences correlated inversely with sympathetic nerve activity (r = -0.76, p<0.0001) with the highest sympathetic activity observed in patients with reverse dipping. 9 The Dublin Outcome Study included 5292 hypertensive patients and demonstrated that nocturnal BP was an independent predictor of cardiovascular mortality. 25 A 10-mmHg increase in mean nighttime SBP corresponded to a 21% increase in cardiovascular mortality. The Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) ABPM substudy has demonstrated that nighttime SBP is superior compared to office SBP in predicting stroke. 26 Herein, RDN significantly reduced both nighttime SBP by 11.9 mmHg, 10.9 mmHg and 12.6 mmHg (p<0.0001) and daytime SBP by 13.6 mmHg, 10.7 mmHg, and 11.6 mmHg (p<0.0001) at 3, 6 and 12 months, respectively.
However, no clear improvement in dipping status was found after RDN, which might be related i) to the poor reproducibility of the classification of patients into dippers and non-dippers over time 27, 28 and ii) to the fact that ABPM was performed as usually done in clinical practice with fixed time intervals for day and night time periods, which might affect the calculation of nocturnal dipping.
The office BP reductions were more pronounced than the reduction in ABPM, a plausible finding which has been consistently demonstrated in antihypertensive drug treatment trial. 29 In a meta-analysis including 44 studies with >5800 patients, the averaged weighted reductions in 24-ndependent predictor of cardiovascular mortality. 25 A 10-mmHg increase in mea ea an n ni n gh gh ghtt tt ttim im ime e e SBP corresponded to a 21% increase in cardiovascular mortality. The Anglo-Scandinavian Ca Card rd rdia ia iac c c Ou Ou Outc t tcom ome e e T Tr Trial (ASCOT) ABPM substud ud udy y h has demonstrat at a ed t tha ha hat t nighttime SBP is u upe e peri r or compa par re ed d d to o o off ff ffic ic ice e e SB SB SBP P in in in p pr re ed d dictin in ng g g stro ok k ke. 26 hour SBP or DBP were 36.5% and 36.8% less than the reduction in the office based values. 29 The differences between office BP and 24-hour BP reductions found herein might be partially influenced by other factors, including a possible regression to the mean of office BP readings over repeated visits, a phenomenon which by definition cannot affect mean ABP. Furthermore, it can be hypothesized that the disparity might be partially mediated by a suppression of the whitecoat effect, frequently encountered in resistant hypertension and associated with increased sympathetic activity. 30 However, the differences between the entire population and the group of patients with true resistant hypertension were comparable, indicating that this cannot only be pironolactone ne e o o onc nc nce e e da da dail il i y. y. H H How ow owev ev ever er r, , th h he e e di di d ff ff ffer er ere e ent nt nt e e eff ff ffec ects ts ts o o of f f sp sp spir ir iron on o ol ol olac ac acto to tone ne ne o on n n BP BP BP i i in n n th t e particularly after adjustment for mean daytime SBP. 32 Our study might have some limitations. Despite the advantages of ABPM, it is not generally used in prospective trials investigating cardiovascular protection by antihypertensive treatments. Actually there is not a single prospective study relating BP changes by ABPM to future cardiovascular outcome, which might be due to difficulties of the procedure (time consumption, repeated device checking, data heterogeneity, costs, etc.). 29 It can be speculated that such a profound reduction of BP after RDN might have increased patient's exercise capacity and daily physical workload and thereby also increased ABP, especially during daytime, which might explain the similar BP reductions during daytime and nighttime. Although, preliminary data suggest that RDN reduces BP variability, 38 assessment of BP variability was not part of the study protocol. As the study was mainly focused on the BP changes after 3 or 6 months, the number of patients completing 12-month follow-up is lower compared to the other time points.
Therefore, the group of patients with 12-month follow-up should be regarded as a subgroup, illustrating that the effects of RDN on BP are sustained over a longer time period. Changes in antihypertensive drug treatment might also have influenced ABP measurements. During the study period antihypertensive treatment was reduced in 24.6% (85 patients), due to symptomatic hypotension with SBP <120 mmHg, and increased in 4.6% (16 patients, all non-responders).
Even after censoring for post-procedural medication changes, no significant differences were found, making a relevant influence of treatment intensification unlikely.
Conclusions
Renal denervation reduces office, 24-hour, daytime, nighttime, maximum and minimum BP in patients with true-treatment resistant hypertension on top of background antihypertensive medication. In the largest cohort of patients analyzed so far, RDN was equally effective in terms tudy protocol. As the study was mainly focused on the BP changes after 3 or 6 m m mon on nth h hs, s, s, t t the he he number of patients completing 12-month follow-up is lower compared to the other time points.
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